Comparison · NCT01396083-eef1ed7a
Ranibizumab vs Dexamethasone: Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ranibizumab vs Dexamethasone: Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline. Trial comparisons, record NCT01396083-eef1ed7a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01396083-eef1ed7a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.758 | 0.676 | 0.825 | wilson | |
| Risk in group 2 | 0.882 | 0.812 | 0.929 | wilson | |
| Risk difference, group 1 minus group 2 | -0.124 | -0.219 | -0.0273 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.859 | 0.763 | 0.968 | log | |
| Odds ratio, group 1 over group 2 | 0.418 | 0.209 | 0.835 | log | |
| Number needed to treat, for one fewer participant with the outcome on Ranibizumab than on Dexamethasone | 8.05 | 4.57 | 36.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ranibizumab | Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally | 94 | 124 | OG000 |
| Group 2 | Dexamethasone | Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months | 105 | 119 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline
- Description
- The proportion of patients with ≥ 10% increase in Internal Ocular Pressure (IOP) compared to baseline at any post-baseline visit.
- Time frame
- Baseline, month 6
- Population
The Safety Set consisted of all patients from the RS who had received at least one application of study treatment and had at least one post-baseline safety assessment. Patients were analyzed according to treatment received. The statement that a patient had no adverse events also constituted a safety assessment
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
- NCT number
- NCT01396083
- Phases
- PHASE3
- Conditions
- Visual Impairment, Macular Edema, Central Retinal Vein Occlusion
- Interventions
- Ranibizumab, Dexamethasone implant and sham injections
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2015-02-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01396083?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01396083-eef1ed7a